by Jason Wasserman MD PhD FRCPC and David Li MD
May 29, 2025
Sézary syndrome is a rare type of cancer involving specific white blood cells called T cells. Normally, T cells help fight infections and diseases. In Sézary syndrome, these cells become cancerous and multiply out of control. The cancerous T cells, known as Sézary cells, exhibit a unique, folded appearance under the microscope. These abnormal cells accumulate in the skin, causing widespread redness and irritation (erythroderma), in the lymph nodes, resulting in swelling, and the bloodstream.
The most common symptoms of Sézary syndrome include:
Some patients might also experience an increased risk of developing other cancers due to weakened immunity.
The exact cause of Sézary syndrome is unknown. However, recent studies suggest that exposure to ultraviolet (UV) radiation plays a significant role in this process. UV radiation is thought to damage T cells in the skin, leading to mutations that transform normal T cells into cancerous Sézary cells. Genetic changes affecting various pathways involved in immune system regulation and DNA repair also contribute to disease development.
Sézary syndrome is a very rare condition, affecting a small number of adults. It typically occurs in people older than 60 and is more common in men than in women. Sézary syndrome accounts for a small percentage (approximately 2-3%) of all skin-related T cell cancers.
Sézary syndrome primarily affects the skin, causing widespread redness (erythroderma). It often involves lymph nodes, causing them to swell. In more advanced stages, it can spread to internal organs, such as the lungs, mouth, and throat (oropharynx), as well as the central nervous system.
To diagnose Sézary syndrome, your doctor will typically evaluate blood samples, skin biopsies, and lymph node biopsies. A pathologist examines these samples under the microscope, looking for Sézary cells, which have distinctive folded nuclei. These cells must be identified in blood and tissue samples from the skin or lymph nodes to confirm the diagnosis. Bone marrow biopsies may occasionally be used to identify Sézary cells, although their presence is usually sparse in this tissue.
Several specialized tests can confirm Sézary syndrome:
Sézary syndrome is an aggressive disease, and its prognosis varies based on the stage at diagnosis. The median survival is approximately 32 months, with 5-year survival rates ranging from 10% to 30%. Patients often succumb to infections due to weakened immunity. Early detection and ongoing management by specialists can improve outcomes and help control symptoms.